AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Sanofi Extends Takeover Bid for Blueprint Medicines to July 17
ByAinvest
Thursday, Jul 17, 2025 2:42 am ET1min read
Sanofi extends its takeover bid for Blueprint Medicines by one day, with the new expiry date set for 5:00 p.m. EDST on 17 July. As of now, 29,742,419 shares (45.85% of the total outstanding shares) have been validly tendered and 23,400,152 shares have been tendered by guaranteed delivery notice. The tender offer price is $129 per share, plus a contingent non-transferable contractual right per share.
Sanofi has extended its takeover bid for Blueprint Medicines Corporation by one day, with the new expiry date set for 5:00 p.m. EDST on July 17, 2025. The initial tender offer, which was scheduled to expire at 12:01 a.m. EDST on July 17, 2025, has been extended to allow more time for shareholders to tender their shares.As of the close of business on July 16, 2025, approximately 29,742,419 shares, representing 45.85% of the total outstanding shares of Blueprint, have been validly tendered. Additionally, 23,400,152 shares have been tendered by notice of guaranteed delivery, representing approximately 36.08% of the outstanding shares. These shares are not deemed validly tendered until they are delivered to the depositary prior to the offer's expiration.
The tender offer price stands at $129 per share, with an additional non-transferable contractual right per share. This right represents the potential for contingent payments of up to $6.00 per share upon the achievement of specified milestones.
The extension of the offer is subject to certain conditions, including the tender of a majority of the outstanding shares of Blueprint’s common stock. The offer is being made pursuant to the terms and conditions described in the offer to purchase, dated June 17, 2025, as amended. Holders of shares who have already tendered their shares do not need to re-tender or take any further action.
For more information, shareholders can contact Innisfree M&A Incorporated at +1 877 750-0831 or +1 212 750-5833.
[1] https://finance.yahoo.com/news/press-release-sanofi-announces-extension-050000353.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet